Format

Send to

Choose Destination
J Antimicrob Chemother. 2009 Apr;63(4):713-5. doi: 10.1093/jac/dkp002. Epub 2009 Jan 22.

Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.

Author information

1
Antibiotic Resistance Monitoring and Reference Laboratory, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW95EQ, UK. david.livermore@hpa.org.uk

Abstract

BACKGROUND:

TR-700 is the active moiety of TR-701 (DA-7157), a new oral/intravenous oxazolidinone prodrug. We examined its activity against linezolid-susceptible and -resistant staphylococci and enterococci.

METHODS:

MICs were determined by the CLSI agar dilution method.

RESULTS:

MICs of TR-700 were tightly clustered around 0.5 mg/L for linezolid-susceptible staphylococci and enterococci compared with 2 mg/L for linezolid. MICs for 52 linezolid-resistant isolates were raised, but only exceeded 4 mg/L for two Enterococcus faecium isolates homozygous for the G2576T 23S rRNA mutation and for one with an unknown mechanism of linezolid resistance.

CONCLUSIONS:

TR-700 is 4- to 16-fold more active than linezolid and overcame most linezolid resistance in vitro.

PMID:
19164418
DOI:
10.1093/jac/dkp002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center